Schrodinger (STU:43Z) Interest Expense : €0.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Schrodinger Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Schrodinger's interest expense for the three months ended in Dec. 2024 was € 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was €0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Schrodinger's Operating Income for the three months ended in Dec. 2024 was € -19.8 Mil. Schrodinger's Interest Expense for the three months ended in Dec. 2024 was € 0.0 Mil. GuruFocus does not calculate Schrodinger's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Schrodinger Interest Expense Historical Data

The historical data trend for Schrodinger's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Schrodinger Interest Expense Chart

Schrodinger Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

Schrodinger Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Schrodinger Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Schrodinger (STU:43Z) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Schrodinger's Interest Expense for the three months ended in Dec. 2024 was €0.0 Mil. Its Operating Income for the three months ended in Dec. 2024 was €-19.8 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was €96.5 Mil.

Schrodinger's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate Schrodinger's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Schrodinger Inc has enough cash to cover all of its debt. Its financial situation is stable.

Schrodinger Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Schrodinger Inc (STU:43Z) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SDGR:USA 43Z:Germany

Address

1540 Broadway, 24th Floor, New York, NY, USA, 10036

Website

https://www.schrodinger.com

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Schrodinger Headlines

No Headlines